Miriam J Smith, Emma R Woodward, D Gareth Evans
Recent genetic sequencing studies in large series' of predominantly childhood medulloblastoma have implicated loss-of-function, predominantly truncating, variants in the ELP1 and GPR161 genes in causation of the MBSHH subtype specifically. The latter association, along with a report of an index case with some features of Gorlin syndrome has led to speculation that GPR161 may also cause Gorlin syndrome. We show that these genes are associated with relatively low absolute risks of medulloblastoma from extrapolating lifetime risks in the general population and odds ratios from the population database gnomAD...
March 24, 2023: Familial Cancer
Amye M Harrigan, Amy M Trottier
Acute myeloid leukemia with germline CEBPA mutation is a subtype of acute myeloid leukemia that is associated with a favorable prognosis. Most of the reported cases of acute myeloid leukemia with CEBPA germline variants involve a germline variant in the N-terminus and a somatic variant in the C-terminus. There are only a few reported cases where the CEBPA germline variant has been identified in the C-terminus and the somatic variant in the N-terminus. This case report and review of the literature illustrates that, although acute myeloid leukemia with CEBPA N- or C-terminal germline variants have certain similarities such as atypically young age at diagnosis, frequent relapse, and favourable overall prognosis, there are also significant differences such as lower life-time penetrance of acute myeloid leukemia and shorter time to relapse for germline C-terminal cases...
March 6, 2023: Familial Cancer
Bettina Lehman, Elvira Matthäi, Norman Gercke, Ulrike W Denzer, Jens Figiel, Timo Hess, Emily P Slater, Detlef K Bartsch
Familial pancreatic cancer (FPC) is a rare hereditary tumor entity with broad phenotypic heterogeneity, including colorectal carcinoma (CRC) in some families. The underlying factors for this co-occurrence are still not well evaluated. FPC families in the National Case Collection of Familial Pancreatic Cancer with an additional occurrence of CRC were analyzed regarding the phenotype, genotype and recommendation for a clinical screening program. The total cohort of 272 FPC families included 30 (11%) families with at least one CRC case...
January 31, 2023: Familial Cancer
James G Dowty, Chenglong Yu, Mahnaz Hosseinpour, Jihoon Eric Joo, Ee Ming Wong, Tu Nguyen-Dumont, Joseph Rosenbluh, Graham G Giles, Roger L Milne, Robert J MacInnis, Pierre-Antoine Dugué, Melissa C Southey
DNA methylation marks that are inherited from parents to offspring are known to play a role in cancer risk and could explain part of the familial risk for cancer. We therefore conducted a genome-wide search for heritable methylation marks associated with prostate cancer risk. Peripheral blood DNA methylation was measured for 133 of the 469 members of 25 multiple-case prostate cancer families, using the EPIC array. We used these families to systematically search the genome for methylation marks with Mendelian patterns of inheritance, then we tested the 1,000 most heritable marks for association with prostate cancer risk...
January 28, 2023: Familial Cancer
(no author information available yet)
No abstract text is available yet for this article.
January 23, 2023: Familial Cancer
Timo A Kumpula, Susanna Koivuluoma, Leila Soikkonen, Sandra Vorimo, Jukka Moilanen, Robert Winqvist, Tuomo Mantere, Outi Kuismin, Katri Pylkäs
CHEK2 is a well-established breast cancer susceptibility gene. The most frequent pathogenic CHEK2 variant is 1100delC, a loss-of-function mutation conferring 2-fold risk for breast cancer. This gene also harbors other rare variants encountered in the clinical gene panels for hereditary cancer. One of these is CHEK2 c.1312 G > T, p.(Asp438Tyr) in the kinase domain of the protein, but due to its rarity its clinical significance for breast cancer predisposition has remained unclear. Here, we tested the prevalence of CHEK2 p...
January 19, 2023: Familial Cancer
Ixtaccihuatl H Obregón, Kelvin C de Andrade, Renee C Bremer, Payal P Khincha, Sharon A Savage
No abstract text is available yet for this article.
January 11, 2023: Familial Cancer
Lindsey Byrne, Cana Ingalls, Aliya Ansari, Cassie Porteus, Talia R Donenberg, Daniel A Sussman, Colleen M Cebulla, Mohamed H Abdel-Rahman
Germline pathogenic variants in the tumor suppressor gene BAP1 are associated with the hereditary tumor predisposition syndrome with susceptibility to uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other cancers. Germline BAP1 pathogenic variants are rare in the non-cancer general population with an estimated carrier frequency of 1:19,898 but more common in cancer patients with a carrier frequency of 1:1299. In the following we present the first report of a family with two unique BAP1 pathogenic variants...
December 14, 2022: Familial Cancer
Ahmed Bouras, Pierre Naibo, Clémentine Legrand, François Le Marc'hadour, Eric Ruano, Chloé Grand-Masson, Cedrick Lefol, Qing Wang
The PMS2 gene is one of the DNA mismatch repair genes (MMR) implicated in Lynch syndrome (LS). A subset of PMS2 pathogenic variants (PVs) are splice variants mostly affecting canonical GT/AG splicing sequences. However, the majority of the intronic variants outside canonical splice sites remained as variants of unknown significance, even though some of them would alter the splicing process. In this report, we describe the analysis of such an intronic variant (c.251-5T > C) detected in an 82-year-old patient diagnosed with endometrial cancer displaying microsatellite instability and the loss of PMS2 expression displayed...
November 29, 2022: Familial Cancer
Meera Kattapuram, Christina Shabet, Sarah Austin, Michelle F Jacobs, Erika Koeppe, Emily H Smith, Lori Lowe, Tobias Else, Kelly B Cha
Immunohistochemistry (IHC) of cutaneous sebaceous lesions (SL) can be used to screen patients for Lynch syndrome (LS). There is little data on rates of genetic referral and outcomes of genetic testing for patients with SL. This single-center retrospective study characterizes 400 + patients with SL, including IHC results, genetics referrals, and outcomes of genetic testing. Retrospective chart reviews were performed for patients with a pathology-confirmed diagnosis of SL at the University of Michigan between January 2009 and December 2019...
November 28, 2022: Familial Cancer
Shahram Aziz, Hazel O'Sullivan, Kara Heelan, Afrina Alam, Terri P McVeigh
A subset of patients with Lynch Syndrome demonstrates cutaneous manifestations of the disorder. Characterization of these Lynch-related skin lesions could help in early recognition of patients with Lynch Syndrome. A broad search of the literature on OVID Medline and Embase was carried out to capture papers reporting cutaneous manifestations in Lynch Syndrome patients. The results were uploaded into Mendeley reference management software. The PRISMA workflow was used in the literature selection process. In this systematic review, data were collected from 961 cases from 413 studies, including 380 molecularly confirmed Lynch Syndrome cases...
November 23, 2022: Familial Cancer
E Soons, P D Siersema, L M A van Lierop, T M Bisseling, M C A van Kouwen, I D Nagtegaal, R S van der Post, F Atsma
To prevent duodenal and ampullary cancer in familial adenomatous polyposis (FAP) patients, a diagnosis of high grade dysplasia (HGD) plays an important role in the clinical management. Previous research showed that FAP patients are both over- and undertreated after a misdiagnosis of HGD, indicating unwarranted variation. We aimed to investigate the laboratory variation in dysplasia grading of duodenal adenomas and explore possible explanations for this variation. We included data from all Dutch pathology laboratories between 1991 and 2020 by retrieving histology reports from upper endoscopy specimens of FAP patients from the Dutch nationwide pathology databank (PALGA)...
November 19, 2022: Familial Cancer
Trevor L Hoffman, Hilary Kershberg, John Goff, Kimberly J Holmquist, Reina Haque, Monica Alvarado
Variants in hereditary cancer risk genes are frequently identified following tumor-based DNA sequencing and represent an opportunity to diagnose hereditary cancer. We implemented an automated hereditary cancer screening program in a large HMO for all patients who underwent tumor-based DNA sequencing to identify patients with hereditary cancer and determine if this approach augmented existing genetic counseling approaches driven by personal/family history criteria. Regular automated searches of a centralized tumor DNA variant database were performed for ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PALB2, and/or PMS2 variants, and germline hereditary cancer gene panel testing was offered to patients with tumor variants who had never undergone germline testing...
October 20, 2022: Familial Cancer
(no author information available yet)
No abstract text is available yet for this article.
October 19, 2022: Familial Cancer
Madeline Foley, Anu Sharma, Kinley Garfield, Luke Maese, Luke Buchmann, Julie Boyle, Wendy Kohlmann, Joanne Jeter, Samantha Greenberg
Pathogenic variants (PVs) in the SDHD gene increase risk for paragangliomas (PGL)/pheochromocytomas, renal cell carcinomas, and gastrointestinal stromal tumors. Penetrance in individuals with SDHD PVs varies in reported research from 40-70%, and there is limited evidence of specific genotype risks. This study aims to characterize a multi-generational family with SDHD p.Trp43* PVs and potential genotype-phenotype considerations for surveillance. Individuals with a paternally inherited SDHD p.Trp43*(c.129G > A) PV were identified...
October 12, 2022: Familial Cancer
Ryan Matthew Kahn, Muhammad Danyal Ahsan, Eloise Chapman-Davis, Kevin Holcomb, Roni Nitecki, Jose Alejandro Rauh-Hain, Rana Khan Fowlkes, Francesca Tubito, Maira Pires, Paul J Christos, Kaitlyn Tkachuk, Hannah Krinsky, Ravi N Sharaf, Kenneth Offit, Steven Lipkin, Melissa K Frey
Cascade testing for familial cancer syndromes has historically been difficult to execute. As part of a facilitated cascade testing pathway, we evaluated barriers to completion of cascade testing. Our previously published study evaluated a facilitated cascade testing pathway whereby a genetics team facilitated at-risk relative (ARR) cascade testing through telephone genetic counseling and mailed saliva kit testing. This follow-up study evaluated barriers to completion of cascade genetic testing through six-month follow-up telephone interviews...
October 8, 2022: Familial Cancer
M Hoedjes, A Vrieling, L de Brauwer, A Visser, E Gómez García, N Hoogerbrugge, E Kampman
This study aimed to identify determinants of adherence to lifestyle and body weight recommendations for cancer prevention among Lynch Syndrome (LS) patients. Cross-sectional baseline data of LS patients participating in the Lifestyle & Lynch (LiLy) study was used to assess determinants of adherence to the World Cancer Research Fund cancer prevention recommendations on body weight, physical activity, and red and processed meat intake. Adherence and potential determinants of adherence were assessed using questionnaires...
September 24, 2022: Familial Cancer
Vincent M T de Jong, Roelof Pruntel, Tessa G Steenbruggen, Fonnet E Bleeker, Petra Nederlof, Frans B L Hogervorst, Sabine C Linn
An inherited single nucleotide variant (SNV) in the 5'UTR of the BRCA1 gene c.-107A > T was identified to be related to BRCA1 promoter hypermethylation and a hereditary breast and ovarian cancer phenotype in two UK families. We investigated whether this BRCA1 variant was also present in a Dutch cohort of breast and ovarian cancer patients with tumor BRCA1 promoter hypermethylation. We selected all breast and ovarian cancer cases that tested positive for tumor BRCA1 promoter hypermethylation at the Netherlands Cancer Institute and Sanger sequenced the specific mutation in the tumor DNA...
September 16, 2022: Familial Cancer
Terri Patricia McVeigh, Karl J Sweeney, Donal J Brennan, Una M McVeigh, Simon Ward, Ann Strydom, Sheila Seal, Katherine Astbury, Paul Donnellan, Joanne Higgins, Maccon Keane, Michael J Kerin, Carmel Malone, Pauline McGough, Ray McLaughlin, Michael O'Leary, Margaret Rushe, Michael Kevin Barry, Geraldine MacGregor, Michael Sugrue, Ala Yousif, Dhafir Al-Azawi, Eileen Berkeley, Terence J Boyle, Elizabeth M Connolly, Carmel Nolan, Elaine Richardson, Claire Giffney, Samantha B Doyle, Sheila Broderick, William Boyd, Ruaidhri McVey, Thomas Walsh, Michael Farrell, David J Gallagher, Nazneen Rahman, Angela J George
In the Republic of Ireland (ROI), BRCA1/BRCA2 genetic testing has been traditionally undertaken in eligible individuals, after pre-test counselling by a Clinical Geneticist/Genetic Counsellor. Clinical Genetics services in ROI are poorly resourced, with routine waiting times for appointments at the time of this pilot often extending beyond a year. The consequent prolonged waiting times are unacceptable where therapeutic decision-making depends on the patient's BRCA status. "Mainstreaming" BRCA1/BRCA2 testing through routine oncology/surgical clinics has been implemented successfully in other centres in the UK and internationally...
August 27, 2022: Familial Cancer
Elysa Bond, Beverly Yashar, Tobias Else, Jenae Osborne, Monica Marvin
Individuals with genetic disease face unique challenges related to navigating dating relationships. While previous studies have explored the impact of hereditary breast and ovarian cancer syndrome on dating, research investigating psychosocial implications for young adults with early-onset multi-organ tumor predisposition syndromes such as von Hippel-Lindau disease (VHL) is scarce. This study assessed young adults' attitudes towards dating and decisions related to disclosing a diagnosis of VHL to a dating partner...
August 19, 2022: Familial Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.